Fig. 4From: Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis(a) VS and (b) CD4+ CFB at Week 48 with DTG versus comparatorsBack to article page